7/23/2013 7:24:09 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Teva Pharmaceutical Industries expects to complete development of new medicines in the next few years aimed at treating brain disorders as the global population ages, its chief executive said. Israel-based Teva, the world's largest generic drugmaker, is seven months into a sweeping reorganisation as it seeks to mitigate lost revenue from increased competition from copies of its best-selling branded multiple sclerosis drug Copaxone. Teva is investing $15 million over five years and has already given grants to more than 50 projects at Israeli universities to tackle diseases such as Alzheimer's, Huntington's, Parkinson's and amyotrophic lateral sclerosis (ALS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by